Clinical Trial AdvancementsPositive FDA feedback brings annamycin one step closer to clinical evaluation in pediatric cancer patients.
Financial StrategyThe company was able to successfully complete two transactions under more favorable terms, including a warrant inducement transaction and a registered direct offering, which combined raised $9.3M.
Regulatory ProgressThe recent approval further expands the reach of the global approval study and bolsters enrollment efforts, which already includes clinical sites in the U.S., Europe, and the Middle East.